Ultragenyx Pharmaceutical Inc expected to post a loss of $1.61 a share - Earnings Preview

Ultragenyx Pharmaceutical

02/05/2025 22:35

Ultragenyx Pharmaceutical Inc RARE.OQ RARE.O is expected to show a rise in quarterly revenue when it reports  results on May 6 for the period ending March 31 2025

The Novato California-based  company is expected to report a 32.2% increase in revenue to $143.826 million from $108.83 million a year ago, according to the mean estimate from 16 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Ultragenyx Pharmaceutical Inc is for a loss of $1.61 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 1.0% in the last three months. ​

Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $86.00​, above​ its last closing price of $38.97. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.20
-1.29
-1.39
Missed
-7.7
Sep. 30 2024
-1.50
-1.45
-1.40
Beat
3.5
Jun. 30 2024
-1.66
-1.69
-1.52
Beat
10.3​
Mar. 31 2024
-1.76
-1.73
-2.03
Missed
-17.2
​​Dec. 31 2023
-1.66
-1.62
-1.52
Beat
6.1
Sep. 30 2023
-2.28
-2.08
-2.23
Missed
-7.3​
Jun. 30 2023
-2.08
-2.07
-2.25
Missed
-8.5
Mar. 31 2023
-2.04
-1.98
-2.33
Missed
-17.9

This summary was machine generated May 2 at 21:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)